JP2010521442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521442A5 JP2010521442A5 JP2009553196A JP2009553196A JP2010521442A5 JP 2010521442 A5 JP2010521442 A5 JP 2010521442A5 JP 2009553196 A JP2009553196 A JP 2009553196A JP 2009553196 A JP2009553196 A JP 2009553196A JP 2010521442 A5 JP2010521442 A5 JP 2010521442A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- nsaid
- glycol ether
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 9
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 8
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 3
- -1 fatty acid ester Chemical class 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000001953 sensory Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000000699 topical Effects 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 1
- 229940044949 Eucalyptus oil Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 229960004873 LEVOMENTHOL Drugs 0.000 claims 1
- 229940041616 Menthol Drugs 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 230000002821 anti-nucleating Effects 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 1
- 239000010642 eucalyptus oil Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Claims (23)
- 非ステロイド性抗炎症剤(NSAID)を局所投与するための組成物であって、前記組成物はキャリアシステム中に有効成分としてNSAIDの溶液又は懸濁液を含み、前記キャリアシステムは常温で単一の相として存在し、多価アルコール、グリコールエーテル、及び高級脂肪酸エステルを含む、組成物。
- 有効成分としてのNSAIDがジクロフェナクである、請求項1に記載の組成物。
- ジクロフェナクがジクロフェナク酸である、請求項2に記載の組成物。
- 多価アルコールがグリコールである、請求項1〜3のいずれか1項に記載の組成物。
- グリコールがイソプロピレングリコールである、請求項4に記載の組成物。
- エステルが極性脂質である、請求項1〜5のいずれか1項に記載の組成物。
- 極性脂質がC12乃至C20の飽和カルボン酸の分岐鎖アルキルエステルである、請求項6に記載の組成物。
- グリコールエーテルがジエチレングリコールエーテルである、請求項1〜7のいずれか1項に記載の組成物。
- ジエチレングリコールエーテルがジエチレングリコールモノエチルエーテルである、請求項8に記載の組成物。
- キャリアシステム成分を、重量パーセントで示した場合に以下の量で有する、請求項1〜9のいずれか1項に記載の組成物。
多価アルコール 5〜70%
グリコールエーテル 20〜60%
エステル 2〜70% - NSAID量が最大10重量%である、請求項1〜10のいずれか1項に記載の組成物。
- NSAID量が最大5重量%である、請求項11項に記載の組成物。
- NSAID量が最大2.5重量%である、請求項12項に記載の組成物。
- 多価アルコール対グリコールエーテルの比率が80:20乃至30:70の範囲であり、エステルが2〜20重量%の範囲である、請求項1〜13のいずれか1項に記載の組成物。
- 多価アルコール対グリコールエーテルの比率が70:30乃至40:60の範囲であり、エステルが3〜10重量%である、請求項14に記載の組成物。
- さらに揮発性の溶媒を含む、請求項1〜15のいずれか1項に記載の組成物。
- 揮発性の溶剤が最大5個の炭素原子を含む低級アルコール又は液相ケトンである、請求項16に記載の組成物。
- 低級アルコールがエタノールである、請求項17に記載の組成物。
- さらに抗核形成剤を含む、請求項1〜18のいずれか1項に記載の組成物。
- 知覚信号物質を含む、請求項1〜19のいずれか1項に記載の組成物。
- 知覚信号物質がメンソール及びユーカリ油である、請求項20に記載の組成物。
- 人体又は動物体の標的部位へNSAIDを投与するための局所組成物であって、前記組成物が常温で単一の相として存在する組成物の製造における、多価アルコール、グリコールエーテル及び高級脂肪酸エステルを含むキャリアシステムの使用。
- 人体又は動物体の標的部位へ投与することによる疼痛又は炎症の緩和方法において使用される請求項1〜21のいずれか1項に記載の局所組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0704846.5A GB0704846D0 (en) | 2007-03-13 | 2007-03-13 | Topical pharmaceutical formulation |
PCT/GB2008/000540 WO2008110741A2 (en) | 2007-03-13 | 2008-02-15 | Topical pharmaceutical formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010521442A JP2010521442A (ja) | 2010-06-24 |
JP2010521442A5 true JP2010521442A5 (ja) | 2011-04-14 |
Family
ID=37988913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009553196A Pending JP2010521442A (ja) | 2007-03-13 | 2008-02-15 | 局所製剤処方 |
Country Status (21)
Country | Link |
---|---|
US (1) | US8541470B2 (ja) |
EP (2) | EP2131813B1 (ja) |
JP (1) | JP2010521442A (ja) |
CN (1) | CN101663022A (ja) |
AU (1) | AU2008224735B2 (ja) |
BR (1) | BRPI0808887A2 (ja) |
CA (1) | CA2680074C (ja) |
CO (1) | CO6220926A2 (ja) |
DK (1) | DK2131813T3 (ja) |
ES (1) | ES2391914T3 (ja) |
GB (1) | GB0704846D0 (ja) |
MX (1) | MX2009009758A (ja) |
MY (1) | MY149545A (ja) |
NZ (1) | NZ579895A (ja) |
PL (1) | PL2131813T3 (ja) |
PT (1) | PT2131813E (ja) |
RU (1) | RU2468794C2 (ja) |
SG (1) | SG179480A1 (ja) |
TW (1) | TWI367110B (ja) |
UA (1) | UA100509C2 (ja) |
WO (1) | WO2008110741A2 (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004290862B2 (en) * | 2003-11-20 | 2010-06-03 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
CA2741029A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
US8445696B2 (en) | 2009-10-14 | 2013-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
CN102946859B (zh) | 2010-02-26 | 2016-03-02 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
EP2838902B1 (en) | 2012-04-12 | 2018-12-05 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
WO2014108573A1 (en) * | 2013-01-14 | 2014-07-17 | Biocopea Limited | Solid solution compositions and use in chronic inflammation |
CN104968330A (zh) * | 2013-01-14 | 2015-10-07 | 因佛斯特医疗有限公司 | 用于治疗剧痛的组合物及方法 |
EP2950821A1 (en) * | 2013-02-04 | 2015-12-09 | InFirst Healthcare Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US9012402B1 (en) | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
US9682033B2 (en) | 2015-02-05 | 2017-06-20 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
GB201502845D0 (en) * | 2015-02-20 | 2015-04-08 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
FR3041534B1 (fr) * | 2015-09-30 | 2019-03-15 | Vetoquinol Sa | Composition de nettoyant auriculaire |
GB201609968D0 (en) | 2016-06-07 | 2016-07-20 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
US20210137829A1 (en) * | 2017-03-07 | 2021-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Topical delivery systems for active compounds |
US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
TWI783890B (zh) | 2017-08-24 | 2022-11-11 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
CA3165359A1 (en) | 2020-02-18 | 2021-07-22 | Dorthe Kot Engelund | Glp-1 compositions and uses thereof |
GB2596286B (en) | 2020-06-20 | 2023-01-25 | Francis Davis Adrian | Adherence to topical therapy |
GB2597526A (en) | 2020-07-27 | 2022-02-02 | Incanthera R&D Ltd | Topical formulation |
KR20230047375A (ko) | 2020-07-27 | 2023-04-07 | 인칸테라 (알앤디) 리미티드 | 국소 제형 |
GB202012836D0 (en) | 2020-08-17 | 2020-09-30 | Futura Medical Developments Ltd | Topical composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06104624B2 (ja) * | 1986-05-07 | 1994-12-21 | 太郎 小木曽 | 経皮吸収剤 |
PE20011092A1 (es) * | 2000-02-14 | 2001-11-12 | Procter & Gamble | Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel |
DE10019171A1 (de) * | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
AR041021A1 (es) * | 2002-08-22 | 2005-04-27 | Novartis Consumer Health Sa | Composicion topica |
US7132452B2 (en) * | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
EP1588697A1 (en) | 2004-04-16 | 2005-10-26 | Kurt H. Prof. Dr. Bauer | Emulsion gel for topical application of pharmaceuticals |
US20050244522A1 (en) | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
-
2007
- 2007-03-13 GB GBGB0704846.5A patent/GB0704846D0/en not_active Ceased
-
2008
- 2008-02-15 RU RU2009136228/15A patent/RU2468794C2/ru active
- 2008-02-15 AU AU2008224735A patent/AU2008224735B2/en not_active Ceased
- 2008-02-15 PT PT08709428T patent/PT2131813E/pt unknown
- 2008-02-15 US US12/530,960 patent/US8541470B2/en active Active
- 2008-02-15 JP JP2009553196A patent/JP2010521442A/ja active Pending
- 2008-02-15 BR BRPI0808887-0A patent/BRPI0808887A2/pt not_active Application Discontinuation
- 2008-02-15 MY MYPI20093774A patent/MY149545A/en unknown
- 2008-02-15 ES ES08709428T patent/ES2391914T3/es active Active
- 2008-02-15 EP EP08709428A patent/EP2131813B1/en not_active Not-in-force
- 2008-02-15 MX MX2009009758A patent/MX2009009758A/es active IP Right Grant
- 2008-02-15 SG SG2012017497A patent/SG179480A1/en unknown
- 2008-02-15 CA CA2680074A patent/CA2680074C/en active Active
- 2008-02-15 DK DK08709428.0T patent/DK2131813T3/da active
- 2008-02-15 UA UAA200910111A patent/UA100509C2/ru unknown
- 2008-02-15 NZ NZ579895A patent/NZ579895A/en not_active IP Right Cessation
- 2008-02-15 WO PCT/GB2008/000540 patent/WO2008110741A2/en active Application Filing
- 2008-02-15 CN CN200880007936A patent/CN101663022A/zh active Pending
- 2008-02-15 EP EP12154983A patent/EP2452671A2/en not_active Withdrawn
- 2008-02-15 PL PL08709428T patent/PL2131813T3/pl unknown
- 2008-02-20 TW TW097105840A patent/TWI367110B/zh not_active IP Right Cessation
-
2009
- 2009-10-08 CO CO09111579A patent/CO6220926A2/es not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010521442A5 (ja) | ||
RU2009136228A (ru) | Фармацевтическая композиция для топического применения | |
JP5734479B2 (ja) | ジクロフェナクの新規な非水性外用溶液およびそれを調製するためのプロセス | |
JP2015527386A5 (ja) | ||
JP5938497B2 (ja) | 抗真菌医薬組成物 | |
JP5654987B2 (ja) | 日光角化症の処置のための局所用組成物 | |
RU2012137785A (ru) | Лечение респираторных заболеваний | |
JP2008540394A5 (ja) | ||
SG177736A1 (en) | Dermal formulations of dp2 receptor antagonists | |
JP2016508158A5 (ja) | ||
JP2012530719A5 (ja) | ||
JP2014185132A5 (ja) | ||
JP2014509655A5 (ja) | ||
NZ598554A (en) | Pharmaceutical compositions and method for treating inflammation in cattle and other animals | |
TW201444553A (zh) | 外用醫藥組成物 | |
JP2014224110A (ja) | ロキソプロフェン含有外用剤組成物 | |
JP2016501205A5 (ja) | ||
ES2452872T3 (es) | Composición farmacéutica que comprende una mezcla solvente y un derivado o análogo de vitamina D | |
JP2018505905A (ja) | 局所医薬製剤 | |
JP2014515407A5 (ja) | ||
JP2014114249A (ja) | 基剤、及び皮膚外用剤 | |
JP2013119528A (ja) | 非水性貼付剤 | |
JP2013503841A5 (ja) | ||
RU2005132004A (ru) | Стабилизированные композиции для местного применения, содержащие кетопрофен | |
JP6253495B2 (ja) | ロキソプロフェンを含有する外用剤組成物 |